ActivBiotics Announces Initiation of Phase II Study in Carotid Atherosclerosis: "ActivBiotics, Inc. announced
today that patient enrollment has begun in a Phase II study examining the
effect of rifalazil, a potent anti-chlamydial antibiotic, on
atherosclerotic changes in the carotid artery. The RESTORE-IT trial
(Randomized Evaluation of Short-Term Rifalazil Treatment on Carotid
Atherosclerosis and Intima Media Thickness)"
If this trial succeeds, it would point to a drug that would reduce plaque build up and help isolate one source of that event.
Thursday, February 15, 2007
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment